Thursday, January 21, 2021

Ajinomoto Bio-Pharma Services and DNDi Partner to Develop Critical Immunomodulator for Cutaneous Leishmaniasis Therapeutic

Must read

Rana Daggubati on the latest discovery+ original ‘Mission Frontline’

Bengaluru, January 19, 2021. Last December, discovery+ announced it was foraying into the world of exclusive Indian originals. Now,...

Grab Your ‘Ticket To Hollywood’ And Catch The Dwayne Johnson Blockbuster ‘Jumanji

Mumbai, 19 January, 2021. In one of the biggest festive offerings on television for 2020, ZEE’s newest pan-network property, ‘Ticket...

A MUSICAL ODE TO THE UNKNOWN SOLDIERS

New Delhi, 19th January 2021. On the occasion of Republic Day, Tabla Wizard Pandit Chaturlal Memorial Society is...

Friends and family try to unravel this mystery in this teaser video of Amazon Prime Video’s The Family Man

MUMBAI, 13 January 2021. Amazon Prime Video today dropped a teaser video of the new season of the much-awaited...

Japan, September 29, 2020.

Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce a strategic supply partnership with the Drugs for Neglected Disease Initiative (DNDi), a collaborative, patients’ needs-driven, non-profit drug research and development organization that is developing new treatments for neglected diseases, for the supply of a CpG oligonucleotide, as part of a combination therapy used in the treatment of cutaneous leishmaniasis infections. This project is supported by the Global Health Innovative Technology (GHIT) Fund.

As part of this partnership, Aji Bio-Pharma will manufacture CpG-D35, a class of CpG oligonucleotides, which provides a strong immunostimulatory effects. CpG-D35 will be used to stimulate innate immune response in patients as an adjunct to chemotherapies in treating complicated cutaneous leishmaniasis (CL) and post-kala-azar dermal leishmaniasis (PKDL), persisting parasitic infections causing severely disfiguring and stigmatizing skin lesions.

“We are excited to be able to collaborate on this oligonucleotide with DNDi and support them in their efforts to develop and supply this quality of life improving therapeutic for people with leishmaniasis,” said Noriyasu Kataoka, Quality Manager & President, Ajinomoto Bio-Pharma Services Osaka.“We are pleased to be a trusted and innovative partner to our client, while reinforcing our dedication in improving the health of humankind.”

Over one billion people are at risk of leishmaniasis worldwide, which is transmitted by sandfly bites. Cutaneous leishmaniasis is the most common presentation, with about one million new cases annually. Post-kala-azar dermal leishmaniasis is a complication of visceral leishmaniasis, which can appear months or years after completing treatment.

“We are very pleased to be partnering with Ajinomoto Bio-Pharma Services for the supply of promising new therapeutic for the treatment of cutaneous leishmaniasis,”
 said Dr Byron Arana, Head of Cutaneous Leishmaniasis Programme at DNDi“With this partnership, we continue our goal to develop and provide safe and effective cutaneous leishmaniasis therapeutics.”

More articles

Latest article

Tanla partners with Microsoft to launch blockchain-enabled CPaaS platform

Hyderabad, January 20, 2021. Tanla Platforms Limited and Microsoft today announced the launch of Wisely, a block chain-enabled communications...

BRILLOCA LAUNCHES A NEW STORE ‘LIVESPACE’ IN JAIPUR

Jaipur, January 20, 2021. Underlining its commitment to reach its customers across key market in the country, Brilloca, home...

Amway Launches Amway Home Fruit & Veggie Wash

Jaipur, Jan 20, 2021. Amway India, one of the country’s leading FMCG direct selling companies today announced the launch...

Manipal Institute of Technology to organise Faculty Development Program on Control Systems and Sensor Technology

Manipal, January 20, 2021. The department of Instrumentation and Control Engineering, MIT Manipal  is organizing a week long  faculty...

Yellow Messenger and Microsoft strengthen collaboration to transform voice virtual assistants

New Delhi, January 19, 2021. Yellow Messenger, the world’s leading conversational AI platform, has announced a collaboration with Microsoft...
Live Updates COVID-19 CASES